TrueBinding
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, TrueBinding sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
TrueBinding: 4 sponsored US clinical trials, 1 recruiting.
TrueBinding sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinsons Disease (PD), with 1 trials.
Upper-quartile sponsor footprint
TrueBinding sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
NCT06773962
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
NCT05476783
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
NCT05074498
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
NCT04920786
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the TrueBinding pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Parkinsons Disease (PD) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TrueBinding: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
TrueBinding sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this TrueBinding page
4 registered trials is a research-attention snapshot, not an endorsement of TrueBinding or any single study.
- 1 of TrueBinding's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinsons Disease (PD) is the condition TrueBinding studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinsons Disease (PD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
TrueBinding pipeline card: 4 registered trials from official public datasets.Report a data error.